Thelansis

Linear IgA Bullous Dermatosis (LABD) Market Outlook Thelansis’s “Linear IgA Bullous Dermatosis (LABD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Linear IgA Bullous Dermatosis (LABD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

  Linear IgA bullous dermatosis (LABD) is a rare acquired autoimmune subepithelial bullous disease characterized by linear deposition of IgA along the basement membrane zone (BMZ) targeting several autoantigens. The clinical presentation is heterogeneous and can mimic other blistering disorders such as dermatitis herpetiformis and bullous pemphigoid. However, characteristic cutaneous lesions consist of tense arciform bullae in a ‘string-of-pearls’ configuration. LABD can affect adults and children with similar histological and immunopathological features. LABD generally shows spontaneous resolution in children but not adults. Most cases of childhood LABD are idiopathic, but drugs and infections were reported as potential triggering factors. In adults, malignancies and influenza vaccination also may act as triggers. The child appeared restless and distressed by an intense itch. Lesional and perilesional biopsies were taken from the buttocks for histology and direct immunofluoresce...